Synthetic Lethality Program Discovery
Oncology
DiscoveryActive
Key Facts
About Metastate Metabolomics
Founded in 2019 and based in Zurich, Metastate Metabolomics has developed the 'Metastate Brain,' a decision system designed to compress uncertainty in expensive biological R&D. The company offers focused programs that help teams move from data overload to confident next steps, delivering ranked hypotheses and minimum experiment sets. Its business model is centered on project-based engagements rather than traditional software licenses, targeting high-stakes decisions in industrial biotech and diagnostics.
View full company profileOther Oncology Drugs
| Drug | Company | Phase |
|---|---|---|
| Bi-XDC with PROTACs | Coherent Biopharma | IND-enabling |
| Bi-XDC with RPT | Coherent Biopharma | Early-stage |
| mRNA Anticancer Vaccine | Sunshine Biopharma | Preclinical Research |
| Biosimilar Bevacizumab | Organon (2) | Phase 3 |
| Biosimilar Pembrolizumab | Organon (2) | Phase 3 |
| BCL-2 Inhibitor Program | Vincerx Pharma | Preclinical |
| Not specified in provided content | 3Sbio | Various |
| Preclinical Projects | Zion Pharma | Preclinical |
| Attenukine Oncology Candidate | Teva | Phase 1 |
| XEMA Tumor Marker ELISA Kit | XEMA Group | Commercial |
| KRAS inhibitor | Risen Pharma Tech | Preclinical/Phase 1 |
| KEAP1 Activator Program | Vividion Therapeutics | Phase 1 |